ACTRN12618001026213已完成未知
An open-label phase I study to evaluate the safety and tolerability of PolyActiva PA5108 ocular implant when administered intracamerally to the anterior chamber of the eye of participants with ocular hypertension..
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Open Angle Glaucoma classified as grade 3 or 4 on the modified Shaffer-Etienne Scale
- •A pseudophakic intent to treat eye
- •At least one eye with irreversible sight of Snellen 6/60 or worse
- •Currently administering combination eye drop therapy for open angle glaucoma
排除标准
- •Intraocular surgery or cornea/refractive surgery within past 6 months
- •Participants with current uveitis, cystoid macular oedema, cornea oedema or retinal detachment
- •Current Aphakic eyes
- •Significant corneal guttatae
- •Only one eye
- •Uncontrolled infection of the eye
研究者
相似试验
已完成
1 期
A clinical trial to evaluate the safety and immunogenicity of HBI Measles and Rubella vaccine (Live) in two age groups of healthy male subjects.CTRI/2019/04/018635Human Biologicals Institute55
进行中（未招募）
1 期
A Phase 1 Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAS-004, a MEK (1/2) Inhibitor, in Patients with MAPK Pathway-driven Advanced Solid Tumors with a Documented RAS, NF1, or RAF Mutation or Patients who have Failed BRAF/MEK InhibitioSolid TumorsMedDRA version: 20.0Level: LLTClassification code: 10025648Term: Malignant mast cell tumors unspecified site extranodal and solid organ sites Class: 10029104CTIS2024-510900-34-00Pasithea Therapeutics Corp.36
已完成
1 期
A Phase 1 Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Selumetinib, a Selective Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor, in Japanese Paediatric Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable and Symptomatic Plexiform Neurofibromas (PN)JPRN-jRCT2080225326AstraZeneca KK9
已完成
1 期
A clinical study to assess the safety, tolerability & immunogenicity of Measles Rubella(MR) vaccine in 4 to 5 years old healthy children.CTRI/2022/03/040874Biological E Limited24
已完成
1 期
A Phase 1, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti- tumor Activity of AZD9833 in Japanese Women with ER Positive, HER2 Negative Advanced Breast CancerAdvanced Breast CancerJPRN-jRCT2080225373AstraZeneca KK12